SOPHiA GENETICS SA Ordinary Shares - SOPH STOCK NEWS

SOPHiA GENETICS (NASDAQ: SOPH) has announced a collaboration with Agilent to enhance cancer biomarker analysis. The integration of the SOPHiA DDM™ Platform with Agilent's SureSelect Cancer Comprehensive Genomic Profiling Assay Kit will facilitate the identification of multiple biomarkers in cancer research, helping clinical labs improve efficiency and access critical data. This partnership aims to democratize data-driven medicine through advanced analytics and reporting capabilities. The collaboration is currently being tested with TomaLab, a major lab in Italy.

SOPHiA GENETICS reported strong financial results for Q4 and full-year 2022, with total revenue reaching $47.6 million, up 18% year-over-year. Q4 revenue was $13.4 million, a 22% increase from Q4 2021. Excluding COVID-19 revenues, constant currency growth was 39% and 44% respectively. Gross margins hit a record 72% in Q4, while operating losses improved for the third consecutive quarter to $15.1 million. For 2023, SOPHiA guided revenue growth at or above 30% and announced expanded partnerships with AstraZeneca and Qiagen, enhancing its oncology capabilities.

SOPHiA GENETICS (NASDAQ: SOPH) announced a partnership with the University of Arkansas for Medical Sciences (UAMS) to implement the SOPHiA DDM™ platform for clinical oncology research, focusing on hematologic malignancies. This cloud-native platform harnesses AI to analyze next-generation sequencing (NGS) data, allowing for swift insights into blood cancers like leukemia and lymphoma. The collaboration aims to enhance local expertise and quicken data turnaround for clinical researchers, ultimately benefiting patient care in Arkansas, where these cancers rank as the fourth most common type.

QIAGEN N.V. (NYSE: QGEN) has launched the QIAseq Platform Partnership with SOPHiA GENETICS (NASDAQ: SOPH), aimed at improving the compatibility of QIAGEN's NGS kits with digital data-sharing platforms. This collaboration will enable somatic variant detection using QIAseq panels for homologous recombination repair, enhancing research in precision diagnostics. The partnership is set to expand to custom solutions, allowing greater access to data-driven medicine. Notably, QIAGEN has processed about four million samples with their NGS panels, solidifying their position in the genomics market.

SOPHiA GENETICS (Nasdaq: SOPH) has entered into a partnership with QIAGEN (NYSE: QGEN) to integrate QIAseq reagent technology with its SOPHiA DDM™ platform. This collaboration aims to enhance tumor analysis through next-generation sequencing (NGS), specifically supporting somatic variant detection related to homologous recombination repair. The partnership allows customers to access QIAseq panels for improved data analysis, enhancing research capabilities in oncology. Both companies are optimistic about the positive impact on medicine and research.

SOPHiA GENETICS (NASDAQ: SOPH) has announced a collaboration with Synergy Oncology to utilize SOPHiA DDM™ for a new cancer profiling solution named Totality. This innovative partnership aims to enhance the U.S. oncology market by integrating state-of-the-art laboratory technologies. SOPHiA DDM™ employs artificial intelligence to streamline complex data analysis, providing actionable insights for hereditary cancer treatments. Ken Freedman, Chief Revenue Officer, highlighted the significance of this collaboration in democratizing data-driven medicine. The combined technologies promise improved patient outcomes and align with both companies' missions to advance cancer research.

SOPHiA GENETICS (Nasdaq: SOPH) announced that it will release its financial results for Q4 and the full year of fiscal 2022 before the U.S. markets open on March 7, 2023. A conference call will follow at 8:00 a.m. EST to discuss these results and the company's business outlook. The call will be available via a live webcast on the SOPHiA GENETICS Investor Relations website, with a replay accessible afterward. The company focuses on data-driven medicine through its SOPHiA DDM™ Platform, enhancing healthcare solutions across global institutions.

SOPHiA GENETICS (Nasdaq: SOPH) is partnering with AstraZeneca (Nasdaq: AZN) to enhance precision oncology through its SOPHiA DDM™ platform and multimodal technology. This collaboration aims to improve early patient identification, optimize clinical development, and accelerate the use of innovative treatments. The partnership will integrate various data modalities, including radiomics, molecular data, and clinical information, to provide better insights for treatment decisions. Additionally, SOPHiA is conducting its own DEEP-Lung-IV clinical study to identify predictive signatures for lung cancer immunotherapy response.